NCT00518479View on ClinicalTrials.gov

Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression

NACompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2003

Study Completion Date

April 30, 2004

Conditions
HypertensionLeft Ventricular Hypertrophy
Interventions
DRUG

Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD

DRUG

Valsartan 160mg OD; Moxonidine 400mcg OD

Trial Locations (1)

LS1 3EX

Leeds Teaching Hospital NHS Trust, Leeds

All Listed Sponsors
collaborator

The Leeds Teaching Hospitals NHS Trust

OTHER

lead

University of Leeds

OTHER

NCT00518479 - Pathophysiological Mechanisms of Hypertensive LVH:Optimising Regression | Biotech Hunter | Biotech Hunter